Tuesday broker round-up
2nd Apr 2019 12:14
(Sharecast News) - easyJet: Berenberg upgrades to hold with a target price of 1,040p.
Read moreLondon open: Stocks buoyed by China factory PMI, US-China trade news
1st Apr 2019 08:35
(Sharecast News) - Stocks are kicking-off the new quarter on the front foot, helped by stronger-than-expected economic data out of the People's Republic of China and further positive news on the state of US-China trade talks.
Read moreAstraZeneca gets 'breakthrough' status for selumetinib
1st Apr 2019 07:29
(Sharecast News) - AstraZeneca announced on Monday that the US Food and Drug Administration (FDA) has granted 'Breakthrough Therapy Designation' for the MEK 1/2 inhibitor and potential new medicine selumetinib, which it is developing in partnership with Merck & Co.
Read moreAstraZeneca to raise ?2.7bn for cancer collab, bond repayment
29th Mar 2019 08:03
(Sharecast News) - AstraZeneca plans to raise $3.5bn (£2.7bn) in a share placing to fund a new cancer drug collaboration with Japan's Daiichi Sankyo and repay some of its bonds.
Read moreMonday broker round-up
18th Mar 2019 13:37
(Sharecast News) - IWG: RBC Capital Markets upgrades to sector perform with a target price of 260p.
Read moreFDA grants orphan drug designation to AstraZeneca's 'saracatinib'
18th Mar 2019 08:07
(Sharecast News) - AstraZeneca announced on Monday that the US Food and Drug Administration (FDA) has granted 'orphan drug designation' for 'saracatinib' - a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
Read moreTobacco stocks rise after FDA boss Gottlieb quits
6th Mar 2019 09:20
(Sharecast News) - Shares in tobacco companies rose on Wednesday after America's chief drug and tobacco regulator unexpectedly resigned overnight.
Read moreWednesday broker round-up
27th Feb 2019 13:13
(Sharecast News) - Tullow Oil: Jefferies downgrades to hold with a target price of 222p.
Read moreTuesday broker round-up
26th Feb 2019 13:32
(Sharecast News) - BT: Berenberg downgrades to hold with a target price of 260p.
Read moreAstraZeneca's Lynparza shows positive results in pancreatic cancer trial
26th Feb 2019 09:29
(Sharecast News) - AstraZeneca has reported positive results from a phase 3 trial of the Lynparza drug, which met the primary endpoint in a study for metastatic pancreatic cancer.
Read morePharma firms to testify in Congress over drug pricing
26th Feb 2019 08:31
(Sharecast News) - Top executives of pharmaceutical companies are set to testify in front of the Senate Finance Committee on Tuesday as part of an investigation into drug pricing in the US.
Read moreAstraZeneca's Brilinta reaches primary endpoint in phase 3 trial
25th Feb 2019 07:29
(Sharecast News) - AstraZeneca announced on Monday that its phase 3 'THEMIS' trial has met its primary endpoint, and demonstrated that 'Brilinta' (ticagrelor) - when taken in conjunction with aspirin - showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone.
Read moreThursday broker round-up
14th Feb 2019 13:11
(Sharecast News) - AVEVA: Numis downgrades to add with a target price of 3,300p.
Read moreAstraZeneca beats forecasts as new drug sales soar
14th Feb 2019 07:45
(Sharecast News) - AstraZeneca reported a strong fourth quarter, beating market expectations for revenues and earnings, with the drugs colossus guiding to another strong year ahead.
Read moreFDA grants AstraZeneca's Fasenra orphan drug designation
6th Feb 2019 09:04
(Sharecast News) - AstraZeneca said on Wednesday that the US Food and Drug Administration has granted orphan drug designation (ODD) to Fasenra for the treatment of hypereosinophilic syndrome (HES), a group of rare and potentially fatal disorders that can cause progressive damage to any organ in the body.
Read more